Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5298 - The level of somatic mutations as an indicator of overall survival in gastric cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Gastric Cancer

Presenters

Tatiana Kekeeva

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

T. Kekeeva1, A.S. Tanas2, L. Khashimov3, V. Lyadov4, Y. Andreeva5, G. Frank5, L. Zavalishina5, D.V. Zaletaev6, V.V. Strelnikov7

Author affiliations

  • 1 Laboratory Of Epigenetics, Research Centre for Medical Genetics, 115478 - Moscow/RU
  • 2 Epigenetics Lab, Research Centre for Medical Genetics, 115478 - Moscow/RU
  • 3 Pathology, Russian Medical Academy of Postgraduate Education, 123242 - Moscow/RU
  • 4 Surgery, Treatment and Rehabilitation Center, Moscow/RU
  • 5 Pathology Department, Russian Medical Academy of Continuous Professional Education, Moscow/RU
  • 6 Laboratory Of Medical Genetics, Sechenov First Moscow State Medical University, Moscow/RU
  • 7 Epigenetics, Institute of molecular medicine, Moscow/RU

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5298

Background

Gastric cancer (GC) is a leading cause of cancer deaths. Tumor staging has been conceived as the best predictor of patient survival. Nevertheless, TNM classification has limited power to fully reflect the complicated progression events. Prognosis varies from individual to individual even though the two patients stay in a similar tumor stage, therefore the molecular biology of the individual tumor might be the key point to better understand the nature of GC. The identification of somatic mutations (SM) has the potential to offer diagnostic and prognostic information. The present study is focusing on implementation of clinical exome sequencing for SM identification.

Methods

18 gastric cancer specimens and 18 corresponding adjacent normal gastric specimens were obtained from GC patients with stages from Ia to IV. Paired-ended sequencing was performed using Trusight one sequencing panel (Illumina) on a NEXTSEQ500 platform. 94,5% of the target regions were represented with an average sequencing depth of 20-fold. A somatic variant list was generated for each patient by using MuTect.

Results

Tumor and normal library targeted 4,813 genes associated with known clinical phenotypes were sequenced with mean coverage of 99x. Mean number of detected variations was 7613 per sample. After MuTect filtration the amount of SM was varied from 2 to 414 per sample. We found 692 SM: 5 pathogenic mutations in TP53, ARID1A and HER2 genes, 40 were described in COSMIC and dbSNP database, the rest were novel mutations. By the time of 2 years follow-up, 5 patients (27.8%) died, all of them had intermediate grade adenocarcinoma. Importantly, all of them had dramatic number of SM (from 37 to 414). At the operation moment 3 of them had III stage, 2 of them had 1b and IIa stages. For patients with overall survival (OS) > 2 years the number of SM increases with disease stage: I-II stage from 2 to 12, III stage – from 2 to 20, IV stage – from 12 to 43. For patients with OS < 2 years the number of SM was high nevertheless stage.

Conclusions

We found more than 600 novel mutations, from them 18 mutations were localized in genes previously associated with gastric cancer pathogenesis. In the current moment of the investigation patients with high level of SM have unfavorable prognosis (OS less than 2 year) regardless of stage.

Clinical trial identification

Legal entity responsible for the study

Research Center of Medical Genetics, Moscow, Russia.

Funding

State assignment of FASO Russia.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.